#IMvigor011
LightNews LightNews
oncodaily.bsky.social
IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IMvigor011 #Atezolizumab #BladderCancer
IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer - OncoDaily
IMvigor011 Trial Reports ctDNA as Predictor of Response to Adjuvant Atezolizumab in Bladder Cancer / atezolziumab, bladder cancer, cancer, Cancer research,
oncodaily.com
August 19, 2025 at 1:09 AM
nejm.org
New in the December 18/25, issue of NEJM:

ctDNA-Guided Atezolizumab in Bladder Cancer (IMvigor011 phase 3 trial) nej.md/3WIRtEg

Cardiovascular Outcomes with Tirzepatide (SURPASS-CVOT trial) nej.md/4qd5rLx

#MedSky
Images and descriptions of what's new on NEJM.org this week
December 18, 2025 at 2:01 PM
danafarbernews.bsky.social
FDA approval of adjuvant atezolizumab for ctDNA-positive muscle-invasive bladder cancer marks a major advance in precision oncology, helping personalize treatment after cystectomy. @danafarber.bsky.social’s Dr. Joaquim Bellmunt helped lead the IMvigor011 study supporting approval. bit.ly/3PZdIpQ
Dr. Joaquim Bellmunt of Dana-Farber Cancer Institute
May 26, 2026 at 3:30 PM
nejm.org
After cystectomy for muscle-invasive bladder cancer, many patients are at risk for recurrence. Research findings from the IMvigor011 phase 3 trial are summarized in a new Quick Take video. nej.md/4p0xrB4

#MedSky #Oncology
A visual representation of the IMvigor011 phase 3 trial, which evaluated atezolizumab as compared with placebo as adjuvant therapy in patients at risk for recurrence after cystectomy who tested ctDNA-positive.
December 18, 2025 at 8:00 PM
vhio.bsky.social
#IMvigor011, presented at #ESMO2025 and published in @nejm.org, shows how #liquidbiopsy can personalize post-surgery treatment in #bladdercancer.

➡️ https://linke.to/IMVIGOR011VHIO

@qmbci.bsky.social  @hospitalclinic.bsky.social @tum.de @danafarber.bsky.social
Liquid biopsy guides treatment after surgery for bladder cancer
linke.to
October 24, 2025 at 8:42 AM
natera.com
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit

Read the full announcement here:
www.natera.com/company/news...
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...
www.natera.com
August 18, 2025 at 3:21 PM
katesears.bsky.social
✅ 1st Phase III showing MRD (ctDNA)-guided approach in bladder cancer
➡️ Clinical Tip: ctDNA MRD may personalize care & spare low-risk pts from overtreatment.

#BladderCancer #OncoUrology #Immunotherapy #ctDNA #IMvigor011 #Medicalwatch

natera.com/company/news...
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free surviva...
natera.com
August 19, 2025 at 2:33 PM
nejm.org
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results and Research Summary: nej.md/3WIRtEg
The New England Journal of Medicine ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer A Research Summary based on Powles T et al. | 10.1056/NEJMoa2511885 | Published on October 20, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
December 26, 2025 at 2:23 PM
myesmo.bsky.social
#ESMO25: Atezolizumab prolonged DFS in #ctDNA+ muscle-invasive #BladderCancer in the IMvigor011 #ClinicalTrial, providing first evidence in support of minimal residual disease-guided adjuvant #immunotherapy in this setting.
#ESMODailyReporter ➡️ https://ow.ly/ythW50XeYRP

October 20, 2025 at 2:47 PM
vhio.bsky.social
L’assaig clínic IMvigor011, presentat a #ESMO2025 i publicat a @nejm.org demostra com la #biòpsialíquida pot orientar el tractament posterior a la cirurgia en el càncer de bufeta.

➡️ https://linke.to/IMVIGOR011VHIO_Cat

@qmbci.bsky.social @danafarber.bsky.social @hospitalclinic.bsky.social @tum.de
October 24, 2025 at 8:51 AM
nejm.org
In muscle-invasive bladder cancer, ctDNA-guided atezolizumab led to longer disease-free survival (9.9 vs. 4.8 months), as well as to longer overall survival (32.8 vs. 21.1 months), than placebo among ctDNA-positive patients. Full IMvigor011 phase 3 trial results: nej.md/3WIRtEg

#ESMO25
Panel A: A graph of investigator-assessed disease-free survival among all patients with ctDNA-positive status who underwent randomization (primary end point). Panel B: A graph of overall survival in the same population (secondary end point).
October 20, 2025 at 2:35 PM
oncoalert.bsky.social
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025
youtu.be/4DAcGeK-Qac

REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OncoAlert Weekly Roundup🚨 August 15-21, 2025 / AMPLIFY201, IMvigor011 Update in #BladderCancer
🎯 Personalization in Cancer Care | OncoAlert Weekly Roundup (Breast, Bladder, GI, Lung, Prostate & More) Description: Welcome to this week’s OncoAlert Weekly Roundup—your 4-minute source for the…
youtu.be
August 21, 2025 at 4:09 PM
medthority.bsky.social
That’s a wrap for this oral abstract session on IMvigor011 trial at #GU26

Missed any insights? Explore on demand congress coverage and expert perspectives on Medthority

ow.ly/zJpy50Yn3UP
February 27, 2026 at 5:37 PM
onclive.bsky.social
Thomas Powles, MD, MBBS, MRCP, discusses implication of ctDNA data from the IMvigor011 trial and evolving strategies in MIBC @ascocancer.bsky.social #GU26 #blcsm #oncology www.onclive.com/shorts/explo...
February 27, 2026 at 6:02 PM
urologytimes.bsky.social
Topline IMvigor011 results: The Signatera ctDNA test identified which patients with MIBC may benefit from adjuvant atezolizumab. Signatera-positive patients had significant improvements in DFS & OS with treatment vs placebo. www.urologytimes.com/view/imvigor...
IMvigor011: ctDNA test can predict adjuvant immunotherapy benefit in MIBC
Patients who were Signatera positive and received treatment with atezolizumab had a statistically significant and clinically meaningful improvement in DFS and OS.
www.urologytimes.com
August 18, 2025 at 3:28 PM
katesears.bsky.social
💡 #MWClinicalTips
📢 IMvigor011 trial: ctDNA-guided adjuvant immunotherapy in MIBC. Natera & Genentech/Roche

✅ Signatera-positive pts + atezolizumab → significant ↑ DFS & OS
✅ Signatera-negative pts → excellent outcomes w/out adjuvant Rx
August 19, 2025 at 2:33 PM
vhio.bsky.social
El ensayo clínico IMvigor011, presentado en #ESMO2025 y publicado en  @nejm.org, demuestra cómo la #biopsialíquida puede guiar el tratamiento tras la cirugía en el #cáncerdevejiga.

➡️ https://linke.to/IMVIGOR011VHIO_Cast

@qmbci.bsky.social @danafarber.bsky.social @hospitalclinic.bsky.social @tum.de
October 24, 2025 at 8:41 AM
albertvilella.bsky.social
From @genomeweb.bsky.social , Natera announced this week that Signatera-positive patients treated with Genentech's Tecentriq (atezolizumab) in the Phase III IMvigor011 trial experienced statistically significant improvements in both disease-free and overall survival.
What are the implications?
August 20, 2025 at 8:01 AM
oncoassist.bsky.social
🚨 New in #Oncology!

💡 Phase III IMvigor011 trial in muscle-invasive bladder cancer reports positive results.

📊 Signatera™ ctDNA MRD–guided approach strongly predicts benefit from adjuvant Atezolizumab (Tecentriq®).

🔗 Read more: bit.ly/ONCOnews19AU-3

#ONCOnews #OncoAlert #OncEd #BladderCancer
August 19, 2025 at 1:36 PM
oncoalert.bsky.social
Dear Colleagues at #ESMO25
A Great pleasure to Introduce our Faculty Dr. Petros Grivas 🇺🇸 from Fred Hutch who talks to us about all of the Exciting #BladderCancer Science being Presented in Berlin

✅ Keynote 905
✅ Disitamab vedotin (DV) plus toripalimab
✅ IMvigor011
And much more
October 18, 2025 at 1:48 PM
medscapefrancais.bsky.social
Cancers de la vessie et de la prostate : l’actualité #ESMO2025
Constance Thibault et Philippe Barthélémy commentent les essais cliniques marquants dans les cancers urologiques. Focus sur les études ALBAN, POTOMAC, IMvigor011, EMBARK, CAPItello, PSMAddition
ms.spr.ly/63321t6Mad
Cancers de la vessie et de la prostate : l’actualité ESMO 2025
Constance Thibault et Philipe Barthélémy commentent les essais cliniques marquants dans les cancers urologiques.
ms.spr.ly
October 25, 2025 at 9:00 AM
natmed.nature.com
⭐Research highlight: #Adjuvant #atezolizumab improved survival outcomes in patients with muscle-invasive #bladdercancer who had no radiographic disease but had detectable circulating tumor DNA in their blood. #IMvigor011 #liquidbiopsy #ESMO NEJM.org
https://www.nature.com/articles/d41591-025-00065-1
Liquid biopsy-guided adjuvant therapy in bladder cancer
Adjuvant atezolizumab improved survival outcomes in patients with muscle-invasive bladder cancer who had no radiographic disease but had detectable circulating tumor DNA in their blood.
www.nature.com
November 14, 2025 at 8:30 PM
natrevclinonc.nature.com
From detection to direction: ctDNA-guided personalized therapy for muscle-invasive bladder cancer
Nature Reviews Clinical Oncology, Published online: 15 December 2025; doi:10.1038/s41571-025-01113-yDespite radical cystectomy, residual urothelial cancer cells can persist undetected in patients with muscle-invasive bladder cancer, silently seeding future relapse. New data from the phase III IMvigor011 trial demonstrate that circulating tumour DNA (ctDNA) can be used to effectively stratify patients by recurrence risk, enabling adjuvant atezolizumab to be delivered selectively to those who are likely to benefit. This precision ctDNA-guided strategy might fundamentally reshape postoperative management through alignment of treatment intensity with molecular risk.
www.nature.com
December 15, 2025 at 8:55 PM
oncoalert.bsky.social
The OncoAlert 🚨 TOP STACK: IMvigor011

In muscle-invasive #BladderCancer after cystectomy, ctDNA-guided adjuvant therapy with atezolizumab significantly improved disease-free and overall survival compared with placebo, while ctDNA-negative patients maintained excellent outcomes w/o additional Tx
October 31, 2025 at 10:00 AM
medthority.bsky.social
Dr. Bellmunt concludes IMvigor011:

🧬 Detectable ctDNA after RC identified higher‑risk pts, while persistent ctDNA− aligned with low risk

💉 Adjuvant atezolizumab promoted ctDNA reduction and clearance which was associated with improved DFS

#GU26 #BladderCancer #MIBC
February 27, 2026 at 5:29 PM